These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 34220802

  • 1. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS, Desai AK, Lelias S, Miah SMS, Terry FE, Khan S, Li C, Yi JS, Ardito M, Martin WD, Kishnani PS.
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [Abstract] [Full Text] [Related]

  • 2. HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
    De Groot AS, Kazi ZB, Martin RF, Terry FE, Desai AK, Martin WD, Kishnani PS.
    Clin Immunol; 2019 Mar; 200():66-70. PubMed ID: 30711607
    [Abstract] [Full Text] [Related]

  • 3. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP, Mingozzi F, van der Marel S, Su Y, Garman R, Ferreira V, Martin W, Scott DW, De Groot AS.
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [Abstract] [Full Text] [Related]

  • 4. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
    Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, Kishnani PS, Chien YH.
    Front Immunol; 2024 Oct; 15():1336599. PubMed ID: 38715621
    [Abstract] [Full Text] [Related]

  • 5. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z, Okamoto P, Keutzer J.
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [Abstract] [Full Text] [Related]

  • 6. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS.
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [Abstract] [Full Text] [Related]

  • 7. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, Rizzo WB, Scherer K, Abdul-Rahman O, Tanpaiboon P, Nampoothiri S, Gupta N, Feigenbaum A, Niyazov DM, Sherry L, Segel R, McVie-Wylie A, Sung C, Joseph AM, Richards S, Kishnani PS.
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [Abstract] [Full Text] [Related]

  • 8. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
    Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, Kishnani PS.
    Am J Med Genet C Semin Med Genet; 2012 Feb 15; 160C(1):40-9. PubMed ID: 22252923
    [Abstract] [Full Text] [Related]

  • 9. Mapping the T helper cell response to acid α-glucosidase in Pompe mice.
    Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW.
    Mol Genet Metab; 2012 Jun 15; 106(2):189-95. PubMed ID: 22494547
    [Abstract] [Full Text] [Related]

  • 10. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK, Baloh CH, Sleasman JW, Rosenberg AS, Kishnani PS.
    Front Immunol; 2020 Jun 15; 11():1727. PubMed ID: 32849613
    [Abstract] [Full Text] [Related]

  • 11. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
    Gupta P, Shayota BJ, Desai AK, Kiblawi F, Myridakis D, Messina J, Tah P, Tambini-King L, Kishnani PS.
    Front Immunol; 2020 Jun 15; 11():1929. PubMed ID: 33013846
    [Abstract] [Full Text] [Related]

  • 12. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
    Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD.
    Am J Hum Genet; 2007 Nov 15; 81(5):1042-9. PubMed ID: 17924344
    [Abstract] [Full Text] [Related]

  • 13. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK, Kazi ZB, Bali DS, Kishnani PS.
    Mol Genet Metab Rep; 2019 Sep 15; 20():100475. PubMed ID: 31193175
    [Abstract] [Full Text] [Related]

  • 14. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, Concolino D, Della Casa R, Deodato F, Donati MA, Fiumara A, Gasperini S, Menni F, Pagliardini V, Sacchini M, Spada M, Taurisano R, Valsecchi MG, Di Rocco M, Bembi B.
    Orphanet J Rare Dis; 2018 Feb 08; 13(1):32. PubMed ID: 29422078
    [Abstract] [Full Text] [Related]

  • 15. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
    Tocan V, Mushimoto Y, Kojima-Ishii K, Matsuda A, Toda N, Toyomura D, Hirata Y, Sanefuji M, Sawada T, Sakai Y, Nakamura K, Ohga S.
    Pediatr Int; 2022 Jan 08; 64(1):e15286. PubMed ID: 36074069
    [Abstract] [Full Text] [Related]

  • 16. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.
    Ngiwsara L, Wattanasirichaigoon D, Tim-Aroon T, Rojnueangnit K, Noojaroen S, Khongkraparn A, Sawangareetrakul P, Ketudat-Cairns JR, Charoenwattanasatien R, Champattanachai V, Kuptanon C, Pangkanon S, Svasti J.
    BMC Med Genet; 2019 Sep 11; 20(1):156. PubMed ID: 31510962
    [Abstract] [Full Text] [Related]

  • 17. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E, Laforêt P, De Antonio M, Corre G, Perniconi B, Taouagh N, Mariampillai K, Amelin D, Mauhin W, Hogrel JY, Caillaud C, Ronzitti G, Puzzo F, Kuranda K, Colella P, Mallone R, Benveniste O, Mingozzi F, French Pompe Registry Study Group.
    Sci Rep; 2016 Nov 04; 6():36182. PubMed ID: 27812025
    [Abstract] [Full Text] [Related]

  • 18. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
    Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, Kishnani PS.
    Mol Genet Metab; 2017 Sep 04; 122(1-2):76-79. PubMed ID: 28648664
    [Abstract] [Full Text] [Related]

  • 19. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT.
    Mol Genet Metab; 2010 Jan 04; 99(1):26-33. PubMed ID: 19775921
    [Abstract] [Full Text] [Related]

  • 20. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J, Sherman A, Doerfler PA, Byrne BJ, Herzog RW, Daniell H.
    Plant Biotechnol J; 2015 Oct 04; 13(8):1023-32. PubMed ID: 26053072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.